SCHEMBL5876674

SCHEMBL5876674

Cc1ccc(S(=O)(=O)n2nc(NC3CCC3)c3c2CC(c2ccccc2)(c2ccncc2)C=C3)cc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.35
MAPK1 P28482 1/20 0.35
NR1H2 P55055 1/20 0.33
NR1H3 Q13133 1/20 0.33
NOD2 Q9HC29 1/20 0.33
NOD1 Q9Y239 1/20 0.33
MEN1 O00255 1/20 0.32
ALDH1A1 P00352 1/20 0.32
KMT2A Q03164 1/20 0.32
TSHR P16473 1/20 0.32
ACHE P22303 1/20 0.32
PDE4A P27815 1/20 0.32
PDE4B Q07343 1/20 0.32
PDE4C Q08493 1/20 0.32
PDE4D Q08499 1/20 0.32
CYP2C19 P33261 1/20 0.32
ATM Q13315 1/20 0.32
CCR6 P51684 1/20 0.31
ADORA3 P0DMS8 1/20 0.31
JAK2 O60674 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5876220 0.97 NR1H2 (0.34) USP2MAPK1NR1H2NR1H3MEN1
SCHEMBL5877652 0.97 ACHE (0.34) USP2MAPK1MEN1ALDH1A1KMT2A
SCHEMBL5876198 0.96 USP2 (0.37) USP2MAPK1NR1H2NR1H3NOD2
SCHEMBL5876928 0.93 CCR6 (0.34) MEN1ALDH1A1KMT2AACHECCR6
SCHEMBL5877418 0.93 ALDH1A1 (0.36) USP2MAPK1NR1H2NR1H3NOD2
SCHEMBL5876012 0.92 NR1H2 (0.36) USP2MAPK1NR1H2NR1H3NOD2
SCHEMBL5876201 0.91 USP2 (0.34) USP2MAPK1NR1H2NR1H3NOD2
SCHEMBL5878064 0.90 USP2 (0.32) USP2MAPK1NR1H2NR1H3NOD2
SCHEMBL5876940 0.90 CYP3A4 (0.35) USP2MAPK1ALDH1A1ACHECYP2C19
SCHEMBL5876000 0.89 CCR6 (0.41) MEN1ALDH1A1KMT2ACYP2C19CCR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7119115-B2 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology AVENTIS PHARMA S.A. (FR) 2006-10-10 US disclosed
US-20040162276-A1 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology AVENTIS PHARMA S.A. (FR) 2004-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040162276-A1 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology IDO1, IDO2, INMT USP2 3250/4885MAPK1 2357/4885NR1H2 556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.